Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 16, 2007

View Archived Issues

DOV reports positive phase Ib data for its lead TRIP in depression

Recent patents cover novel agents for neurologic disorders

Bayer describes new thrombin inhibitors

Roche and Schering-Plough separately claim novel compounds for obesity and related disordes

PRLX-93936's antitumor activity profiled by Prolexys

Recombinant human IL-18 to be tested in NHL

AnGes submits Naglazyme BLA to Japanese Ministry of Health

Fosaprepitant tolerability, bioequivalency with oral aprepitant explored

Genta announces initiation of Genasense named-patient/compassionte program

Enrollment completed for Pervasis' phase II trial of Vascugel for ESRD

FoldRx and CFFT enter collaboration agreement for cystic fibrosis research

Study finds regadenoson safe in subjects with decreased renal function

Polyphenolic grape extract activity may explain cardiovascular benefits of red wine

Recruitment completed for pSivida phase IIa study of BrachySil

Anti-IL-18 antibody ABT-325 profiled at Abbott

Cardiome Pharma reports second quarter 2007 results

New PI3K inhibitor described by Merck Serono

Second quarter 2007 results reported by Biomarin

Avigen initiates AV-411 clinical development in the U.S.

Metabolic discontinues ACV-1 clinical trial

Arpida closes TLT acquisition

Esprit Pharma acquires Sanctura XR marketing rights

EMEA accepts Santhera's filing of SNT-MC17 for Friedreich's ataxia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...